BRISBANE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset
BRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset
-Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year -Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate
BRISBANE, Calif. , Sept. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) (the "Company"), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T
BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies
Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and
Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approachLead candidate TPST-4003 combines proprietary CD7-targeted
BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest" or "Tempest Therapeutics") today announced the appointment of two independent directors, Drake Richey and John Yee,
BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) (the "Company"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children's Applied Gene and Cell Therapy Center
100% complete response ("CR") rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T across two ongoing Phase 1 trials (REDEEM-1 and POEMS-1)Favorable safety
Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003Results support clinical benefit of parallel-structure dual-targeting CAR
Delivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal developmentTech transfer on track to support initiation of
Adds dedicated business development leadership to support Tempest's strategic prioritiesWill lead China outreach and cross-border partnership effortsTo support ongoing partnering discussions for Phase 3-ready amezalpat
